17 research outputs found
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial
The aim of this prospective study was to evaluate the long-term efficacy and safety of hydroxyurea (HU) in patients with sickle cell disease (SCD). Thirty-four patients with sickle cell anemia (hemoglobin S [HbS]/HbS), 131 with HbS/ 0 -thal, and 165 with HbS/ ؉ -thal participated in this trial. HU was administered to 131 patients, whereas 199 patients were conventionally treated. The median follow-up period was 8 years for HU patients and 5 years for non-HU patients. HU produced a dramatic reduction in the frequency of severe painful crises, transfusion requirements, hospital admissions, and incidence of acute chest syndrome. The probability of 10-year survival was 86% and 65% for HU and non-HU patients, respectively (P ؍ .001), although HU patients had more severe forms of SCD. The 10-year probability of survival for HbS/ HbS, HbS/ 0 -thal, and HbS/IVSI-110 patients was 100%, 87%, and 82%, respectively, for HU patients and 10%, 54%, and 66%, for non-HU patients. The multivariate analysis showed that fetal hemoglobin values at baseline and percentage change of lactate dehydrogenase between baseline and 6 months were independently predicted for survival in the HU group. These results highlight the beneficial effect of HU, which seems to modify the natural history of SCD and raise the issue of expanding its use in all SCD patients. (Blood
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001).
Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia
Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
Abstract
Background
Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres.
Methods
This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries.
Results
In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia.
Conclusion
This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/beta-thalassemia
Iron overload is present in several cases of double heterozygous
sickle-cell/beta-thalassemia (HbS/beta-thal). Deferasirox is an orally
administered iron chelator which is effective on iron overloaded
patients with transfusion-dependent anemia. The aim of this study was to
investigate the efficacy and safety of deferasirox on HbS/beta-thal
patients with iron overload. We evaluated 31 adult patients with
HbS/beta-thal (14M/17F; median age 41 years) who had serum ferritin
levels > 1,000 ng/mL and who were sporadically transfused. Total iron
burden was monitored by measuring serum ferritin levels before and
monthly after starting deferasirox, while liver iron concentration and
cardiac iron burden were measured by magnetic resonance imaging (MRI) T2
and T2* parameters at baseline and 12 months after deferasirox
treatment. Deferasirox managed to reduce the mean serum ferritin levels
after 12 months of treatment from 1,989 +/- 923 to 1,008 +/- 776 ng/mL
(P < 0.001). This reduction was accompanied by a significant improvement
on MRI T2* of the liver (from 3.9 +/- 3.2 to 5.8 +/- 3.1 ms; P < 0.01)
and by a comparable improvement of biochemical parameters of liver
function. Mild nausea and diarrhea of grade 1/2 were reported in 25% of
patients within the first month of treatment, but did not re-occur.
These data indicate that deferasirox provided effective control of iron
levels (mainly of the liver) in minimally transfused patients with
HbS/beta-thal, without significant adverse events, at similar doses to
those studied widely for the treatment of patients with thalassemia
syndromes
Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma
Background: R-DA-EPOCH is an effective regimen for PMLBCL, which permits
the omission of consolidative radiotherapy in the majority of patients.
Patient: We describe a 27-year-old female patient, who achieved a
complete remission after treatment with six cycles of R-DA-EPOCH (up to
the final level). At 6 months after the end of treatment, PET/CT
revealed an unexpected, diffusely increased (18)FDG uptake by the bone
marrow. Simultaneously, pancytopenia with monocytosis was observed.
Result: The patient was diagnosed with therapy-related myelodysplastic
syndrome, which rapidly evolved into acute myeloid leukemia (t-MDS/AML)
with MLL rearrangements. She achieved a complete remission after
induction therapy, received an allogenic transplant and remains
disease-free 2 years later. Conclusions: The extremely early onset of
t-MDS/AML, together with the unexpected PET/CT findings make this case
unique and highlights the need for the accurate estimation of the
possible dose-dependent risk of t-MDS/AML after R-DA-EPOCH in the
real-life setting in patients with PMLBCL
Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma
Background: R-DA-EPOCH is an effective regimen for PMLBCL, which permits the omission of consolidative radiotherapy in the majority of patients. Patient: We describe a 27-year-old female patient, who achieved a complete remission after treatment with six cycles of R-DA-EPOCH (up to the final level). At 6 months after the end of treatment, PET/CT revealed an unexpected, diffusely increased 18FDG uptake by the bone marrow. Simultaneously, pancytopenia with monocytosis was observed. Result: The patient was diagnosed with therapy-related myelodysplastic syndrome, which rapidly evolved into acute myeloid leukemia (t-MDS/AML) with MLL rearrangements. She achieved a complete remission after induction therapy, received an allogenic transplant and remains disease-free 2 years later. Conclusions: The extremely early onset of t-MDS/AML, together with the unexpected PET/CT findings make this case unique and highlights the need for the accurate estimation of the possible dose-dependent risk of t-MDS/AML after R-DA-EPOCH in the real-life setting in patients with PMLBCL
Angiogenic Molecules and Inflammatory Cytokines in Patients with Thalassemia Major and Double Heterozygous HbS/Beta-Thalassemia; the impact of Deferasirox.
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
The aim of this prospective study was to evaluate the long-term efficacy
and safety of hydroxyurea (HU) in patients with sickle cell disease
(SCD). Thirty-four patients with sickle cell anemia (hemoglobin S
[HbS]/HbS), 131 with HbS/beta(0)-thal, and 165 with HbS/beta(+)-thal
participated in this trial. HU was administered to 131 patients, whereas
199 patients were conventionally treated. The median follow-up period
was 8 years for HU patients and 5 years for non-HU patients. HU produced
a dramatic reduction in the frequency of severe painful crises,
transfusion requirements, hospital admissions, and incidence of acute
chest syndrome. The probability of 10-year survival was 86% and 65%
for HU and non-HU patients, respectively (P = .001), although HU
patients had more severe forms of SCD. The 10-year probability of
survival for HbS/HbS, HbS/beta (0)-thal, and HbS/IVSI-110 patients was
100%, 87%, and 82%, respectively, for HU patients and 10%, 54%, and
66%, for non-HU patients. The multivariate analysis showed that fetal
hemoglobin values at baseline and percentage change of lactate
dehydrogenase between baseline and 6 months were independently predicted
for survival in the HU group. These results highlight the beneficial
effect of HU, which seems to modify the natural history of SCD and raise
the issue of expanding its use in all SCD patients. (Blood. 2010; 115:
2354-2363